Latest / The Dr. Randi Show / Revance 2.0: The Next Chapter in Aesthetic Innovation — Nadeem Moiz

Transcript

Revance 2.0: The Next Chapter in Aesthetic Innovation — Nadeem Moiz · The Dr. Randi Show

0:03
The views expressed in this podcast are for informational
0:06
purposes only and do not constitute medical advice.
0:09
This episode of the Doctor Randy Show is proudly sponsored by New
0:13
Beauty, the ultimate authority in beauty and aesthetics.
0:16
Whether you're looking for the latest innovations, expert
0:19
insights or trusted recommendations, New Beauty is
0:22
your go to source. Visit newbeauty.com to stay
0:25
ahead of the trends and discover what's next in beauty.
0:28
Now let's get into the episode. Welcome to the Doctor Randy show
0:32
where we explore the intersection of beauty, business
0:35
and innovation and the leaders changing the way we think about
0:39
all three. He is the brand new CEO of
0:42
Revance. He is stepping into aesthetics
0:45
at a pivotal moment and he is leading one of the most talked
0:48
about companies in the industry. Please welcome Nadine Moiz.
0:52
Such a pleasure to be here, Doctor Randy.
0:54
It's just a absolute honor. So I'm very happy to be here.
0:58
Absolutely. Well, we're excited to have you
1:00
here today. I saw the announcement yesterday
1:02
or the day before on LinkedIn, so we feel like we got you just
1:06
at the right time. So I'm going to jump right in.
1:09
You have just stepped into what I would call one of the most
1:12
exciting roles in aesthetics. How does it feel stepping into
1:15
the CEO seat at Revance? Yeah.
1:18
Look, it's super exciting. And you know, we call Revance
1:22
today Revance 2 Point O and as you know, Revance was a publicly
1:26
traded company and in February of this year, Crown Labs, which
1:32
is where I started acquired Revance.
1:34
So today we call it Revance 2 Point O.
1:36
It is super exciting. The team is supercharged, we've
1:39
got just excellent brands and and you know I've been part of
1:43
the Crown story for the last almost five years.
1:46
So it's good to see the story build and again, we are
1:50
absolutely ready to go and just doing great things in the
1:53
market. Well, that's very exciting.
1:56
And for listeners and viewers who may not know the full story,
2:00
how would you describe what revamp stands for right now?
2:04
Well, REVAMP stands for Science based innovation.
2:09
RE event stands for customer centricity.
2:11
Re event stands for bringing excellent top of the line
2:16
products to get patient outcomes, client outcomes and
2:21
our customer outcomes in a way that is just absolutely
2:25
positive. And RE Event stands for hugely
2:29
supporting all the physicians and the providers that are
2:34
helping us in our journey and really supporting our product.
2:38
And so we're absolutely behind all of that and it all really
2:41
starts with science based innovation and really creating
2:45
products and services that are differentiated.
2:50
Sure. And what I've seen is so many
2:52
new innovations coming out of the market over the last, I
2:56
guess 12 months, so many new things that I've seen.
2:59
And let's start talking about that, if that's OK with you.
3:03
The first on the top of our list is probably Daxify.
3:06
There's probably no one who hasn't seen that name come out.
3:09
It's exciting for those of us that have been using these type
3:15
of injectables and knowing that now we can have a longer lasting
3:21
option that's amazing for us, right, Like the running back and
3:25
forth to our clinicians, this is now we can fix that time frame.
3:29
So excited to talk about that a little bit with you.
3:33
So patients are used to going in quarterly and this is a longer
3:38
lasting story. So let's talk about that a
3:40
little bit. Yeah, absolutely.
3:42
Look, it's just a great product. Certainly the duration is 1
3:46
aspect of it. As you know, it also has a
3:48
peptide in it, which is incredible.
3:50
And to us it really differentiates the product and
3:54
what we're hearing from our providers that you know with the
3:57
peptide and the longer duration the patients are feeling
4:01
absolutely elated and it just really gives you this really
4:06
nice glow post the treatment as well.
4:10
This is what we're hearing from our physicians, from our
4:12
providers. So it it really has just a huge
4:15
following. Now what I will share with you
4:18
that awareness for Daxy's relatively low today and we're
4:22
still in the early innings of getting the brand out there and
4:27
getting at people's hands and letting customers and clients
4:31
and patients experience the impact of Daxy, But the results
4:36
are just extremely well received.
4:38
Yeah, I think it's phenomenal just to have options.
4:42
Obviously, you know what our options have been up until now,
4:44
but to have something potentially last, are we talking
4:48
maybe around twice as long, then that's amazing for us, right?
4:51
Amazing for the consumer and probably amazing for the
4:54
injectors as well, right. I also heard that you just
4:58
recently passed one million US vials, Is that correct?
5:02
Yes, like such a huge, huge accomplishments, right, Huge
5:06
accomplishment. So look, it's a massive
5:08
milestone for us. We had a big celebration in our
5:10
office and balloons and all this kind of stuff and the team was
5:13
super excited about that. And again, this is early
5:16
innings. And what I would tell you is
5:19
it's taken us a fewer to get to the million vial mark.
5:22
I think the next million vial is going to be much faster.
5:26
It's definitely at a higher speed and a higher acceleration
5:29
and is definitely getting traction in the market.
5:32
People are talking about it, injectors are talking about it,
5:36
the patients are talking about it that well, this is just
5:38
really true, totally differentiated.
5:40
So a lot of energy, a lot of excitement, and you know, we'd
5:44
love to start expanding the DAC supply franchise outside the USI
5:49
mean, we just think that's a huge, huge opportunity for us as
5:53
well. We're approved in China, we're
5:54
approving in Australia and New Zealand, but we're also looking
5:58
at all these other geographies which we think could hugely
6:01
benefit from the product. Well, I have not had the chance
6:04
to try it yet, but I am looking forward to it.
6:06
And congratulations on the 1,000,000 vials.
6:09
It sounds like you're ready to knock it out of the park right
6:13
now. So it's positioned very well.
6:15
The next thing I would like to talk about is a couple of weeks
6:19
ago I read the article about your new RHA collection with my
6:23
Pivacaine, which is very interesting personally to me and
6:29
I'll tell you why. I am allergic to lidocaine so I
6:32
have had a heck of a time with filler.
6:35
So when I saw this launch, I was screenshotting it and sending
6:38
it, send it to the facial plastic surgeon that does my
6:41
filler and you know, sending it around and I was like finally
6:44
somebody changed it. But obviously you didn't create
6:48
it for me. So what made you do that pivot
6:51
and why and where you looking to go with that?
6:53
Yeah. Well, look, as you know, RHA
6:56
collection is produced by Tioxin and it's just an unbelievable
7:03
filler. And all the studies, all the
7:06
research, all the work that was done by Tioxin leading up to the
7:11
switch from lidocaine to mepivacaine were just extremely,
7:14
extremely well received. And it was just clear that this
7:19
is the right direction to go from an R&D perspective.
7:22
Look, we launched it in August, late August.
7:26
It's been very early days on that.
7:28
But the receptivity is huge. And as you know, RHA collection,
7:32
I would say the best filler in the market and having the
7:36
mepinbicaine in there and just seeing patients just super
7:40
excited just to your story to hear your joy in using that
7:43
product is amazing. So that's the sort of reaction
7:46
we're getting. So, so there's more coming on
7:48
that line up as we get into 2026.
7:50
There's more innovation coming and I think the patients are
7:53
going to be extremely happy when they actually get their hands on
7:56
it. Well thank you for launching
7:59
that product because this will change things for me.
8:02
I've been doing filler with no numbing for a very long time.
8:05
So excited to step into your product next, if you're OK with
8:09
it, let's pivot and talk about skin pen a little bit.
8:12
This has become a go to treatment and I'm curious where
8:17
you see the role of skin pen as well as micro needlings roll
8:22
alongside injectables. That's been a very popular hot
8:25
conversation, so curious what your thoughts are.
8:28
Yeah, look, Skin pen is just doing fantastic and surf it
8:34
comes under the regenerative vertical, right.
8:37
And as you know in this space it just makes a lot of sense to get
8:43
regenerative treatment. Skin pen is like the go to
8:47
device out there. We have skin pen, we also have
8:49
EVO and then we have the third one Elite.
8:52
We have three pens in the market and micro needling is just
8:57
unbelievable and we think that will continue to grow.
9:00
It's doing really well. The stackable treatments, I
9:03
think we're seeing that more than ever, right?
9:06
I think these different combinations and the delivery of
9:08
the results, I think that what I'm noticing is that patients
9:12
today are more educated than ever, right?
9:15
And it sounds like Revance is really adapting to this new
9:19
informed customer by partnering treatments, doing stackable
9:23
treatments. I think that's the way to stay
9:26
on top of things. Absolutely right.
9:27
The patients, they're extremely educated.
9:29
There's so much research they do.
9:32
I see that in my own household. My daughter's 23 does so much.
9:37
She knows so much. I actually take some lessons
9:39
from her at times. But yes, absolutely right.
9:42
And the stacking of procedures, pairing of procedures, I think
9:45
that is the way to go on a lot of these procedures and it just
9:49
makes a lot of sense. Yes, I agree.
9:51
And I think the education comes, I have to be honest, from social
9:55
media, I think that we have a very large group of what I call
10:00
skin fluencers. And not that all of the
10:03
information is truthful, but what it leads consumers to do is
10:07
go do some research on their own.
10:09
They hear something and then they go and do some research and
10:12
start looking into it. So while not all the information
10:14
is accurate, it does kind of prompt people to go do some
10:19
research on those topics and then but we all become a little
10:22
bit more informed. So I think in the end it's a
10:24
good thing. Yeah, absolutely.
10:25
You nailed it. That's exactly right.
10:27
So let's talk about the trends right now in the industry and
10:32
where Revance is going with that.
10:34
So as we all know, aesthetics is a crowded field, it's a
10:38
competitive field. What makes Revance stand apart
10:42
in in such a competitive market? Yeah, look, it's a great
10:45
question. And as you you may know, Revamps
10:49
really has two business segments.
10:52
We obviously have the aesthetics piece, which is a number of
10:55
brands including DAX, Daxify, RHFIT, Oxy and Skin Pen by Juve.
11:00
I mentioned EVO. We also have a very nice
11:03
portfolio of brands on the skin care side which includes Penoxyl
11:07
which is acne treatment, Blue Lizard which is #1 mineral
11:10
sunscreen in the US, Strivecton which is our anti aging and then
11:14
a number of body brands for eczema powders and things like
11:17
that. So it's a very nice portfolio of
11:21
products. And as we think about revamps,
11:25
our goal or aspiration, our true north is to grow both sides of
11:29
the business, which makes sense. And the epicenter of all of this
11:35
will always come back to what I stated earlier.
11:38
These are all products that are science based, innovative
11:43
products. We want to make sure, whether
11:45
it's aesthetics or skin care, we are investing a lot of time,
11:52
resources and capital in research and development and
11:56
formulation and testing. And we want to make sure
11:59
absolutely make sure that the product is differentiated.
12:02
It really has really positive outcomes.
12:05
And the patients or the consumer on the skin care side that's
12:09
buying our product is extremely happy, it's safe, it's efficacy
12:13
and it really, really works. So that's the idea.
12:17
So then you say, OK, well what are the trends?
12:20
So on the aesthetic side, as you know, the regenerative vertical
12:23
is getting a lot of buzz, right, a lot of buzz.
12:26
So we're continuing to do more research and development in that
12:31
space and we can talk about innovation a little bit, but we
12:35
are continuing to expand our portfolio there.
12:37
And I think that's going to be a massive trend.
12:40
The other part of this is GLP ones.
12:42
As you know, that's a huge trend in the world of aesthetics.
12:45
And then that's when you start talking about fillers and we've
12:48
got premier line of filler with RHA filler by Tioxane that we
12:54
think fits extremely nicely in there.
12:56
So that trend will continue with you.
12:58
We've got the right product for that.
13:00
And we also see trends going towards bio simulators.
13:04
And so we're continuing to do research on that piece.
13:07
And then on the skin care side, since this is a broad
13:09
conversation, I'll talk about that as well.
13:11
Skin health for life, anti aging, longevity, these are all
13:15
the trends that we're seeing. As you know, the demographics
13:19
are is aging demographics in the United States.
13:22
People are living longer and people want to be harmonized,
13:26
not transformed. So both on the static side and
13:30
on the skin care side, we're looking at ways to bring
13:34
products that will gently give you harmonization as opposed to
13:37
transformation. So we're obviously watching
13:39
trends on the skin health side, the longevity side of skin
13:43
health and topicals and things like that as we think about the
13:47
skin care side. I'm so glad you brought that up
13:50
because that is usually a topic that I like to hit upon is that
13:54
a lot of patients want now more than ever, a look that's not
14:00
done right. They want a natural result.
14:03
How does revamps kind of shift to that change in demand?
14:08
So what I would say is it's not necessarily a shift for us.
14:12
I would submit to you that we're actually there with this is sort
14:15
of what we're doing today. So when you think about our
14:20
products like we could start, we've got the range of fillers
14:24
right from low, medium, high density, which are straddle the
14:28
world there. And it really is going to come
14:30
down to which practitioner, which physician you're going to
14:32
get your filler treatment. But ultimately, the offering is
14:36
designed to give you a very sort of gentle natural look and give
14:42
you a very nice harmonization look, right.
14:45
So I would say today, we sort of sit there and our goal and our
14:51
aspiration is to stay squarely in the middle of the fairway
14:54
there and continue with the trend there.
14:56
And it sounds like you, you are positioned right in the middle.
14:59
They're not with aggressive treatments that maybe you have
15:02
to dial it back. And you are looking at
15:04
longevity, which is I think the buzzword right now.
15:07
I know I'm doing a webinar coming up on longevity because
15:10
everybody's bringing up the topic of longevity.
15:12
I think we not only want to live longer, but we want to
15:17
capitalize on those years that we're alive on how we look and
15:20
how we feel, right? So I think that has definitely
15:22
become a hot topic. So keeping in mind all of the
15:26
trends and everything that you're doing at Revance, if you
15:30
could say Fast forward five years from now, what do you hope
15:35
that providers and patients are saying about Revance?
15:39
Well, I hope they're saying great things, better events.
15:42
I hope they're saying, boy, these guys are bringing
15:45
excellent science based products that are safe and efficacy.
15:49
And the company Revance stands behind its products.
15:53
They're staying behind the commitment, the very strong
15:57
commitment to investment in research and development and
16:01
science and technology. And they're bringing products
16:05
that are well researched. The clinicals are solid.
16:08
And so those are all the things that we want to be able to hear.
16:12
And it's really a continuation of what's happening today.
16:15
And so again, that's our aspiration on as we think about
16:18
R&D, as we think about research, as we think about how do we
16:21
align our R&D and our scientists that we have, they're brilliant
16:24
by the way, our team, how do we align it so that we're bringing
16:28
in products that ultimately are meeting the needs of the
16:32
patients, right. People want products that will
16:36
help them sculpt themselves in a way that isn't overnight
16:40
transformations right there, safe and efficacy.
16:42
So we're spending a lot of time and dollars there and we're
16:46
doing it with a lot of cognition on that part.
16:48
So I certainly hope in five years from now people will
16:51
continue to say Revance made a commitment to a product thought
16:55
process that delivered on it and we're extremely happy to
16:59
continuing to promote and support us.
17:02
OK, OK, great. And I guess on that topic of
17:07
competition, it is a fierce market, but how do you keep or
17:11
how are you planning I guess to keep Revance focused in its own
17:15
lane instead of reacting to rivals?
17:18
Yeah. Well, it's a great question.
17:20
It is a competitive market, but you know it sort of comes back
17:24
to the genesis of the company. How do we think about the
17:27
portfolio? How do we think about what is
17:29
the place to differentiate ourself?
17:33
Certain aspects that I will point out that differentiates us
17:37
vis A vis the competitive set #1 we've got 2 segments.
17:40
We've got skin care and statics #1 #2 we're vertically
17:44
integrated. So we're not just a pure
17:47
distribution companies. Often times you see in the
17:48
space, in the static space, they're just distributors of
17:52
products that are designed, developed, manufactured outside
17:56
the United States. We are a vertically integrated
17:58
company and significant portion of our portfolio is designed,
18:05
developed, manufactured in the United States.
18:08
DAXIFY is the only, only US manufactured toxin and that's
18:14
being sold in the United States. Everything is imported from
18:17
Europe or Far East. And so we think look, that's a
18:21
differentiator and we'll continue going down that path.
18:24
This is sort of goes back to the inception of the company.
18:28
Jeff Bedard who is the visionary, the founder of Crown
18:31
Labs was adamant about keeping us vertically integrated and I'm
18:35
just grateful for his vision and the platform that he built.
18:39
So we've continued building on that platform and as we think
18:43
about the competitive side, we think that's a competitive
18:44
advantage. We're building a platform and
18:47
building on a platform that is vertically integrated.
18:49
It's got nice two segments. We're investing a lot of money
18:53
on science and technology to bring products in and we have
18:57
the capabilities. These are all in house
18:58
capabilities and so we can come to market faster, we can really
19:04
control our destiny and we can then further to augment all of
19:10
that differentiate on customer centricity, right, Like that's a
19:13
huge aspect of our differentiator Visa, visa
19:16
competitive set. We want to be and we continue to
19:20
be one of the easiest companies to do business with.
19:22
That is absolutely very, very important.
19:24
So when if your question is how do you compete, you really
19:27
compete on product or service or and if you can on both and our
19:32
goal is to continue competing on both.
19:34
OK, well, I think that's a fantastic plan.
19:37
So that works. Let's pivot for just a minute to
19:41
AII have heard that that's a topic that's exciting to you.
19:45
It's always been very exciting to me as well.
19:47
I think I was in the 1st 1000 users of ChatGPT and we see
19:51
where that went, right? So I'm just curious what you
19:55
think and what you see is the role of AI and aesthetics coming
19:59
for us? Yeah, Look, I think Doctor
20:01
Randy, we probably have to do like 2 episodes of another
20:03
podcast just to cover AI. It's just a.
20:08
Broad topic now that we can spend a lot of time talking
20:13
about it and getting excited about it, right?
20:15
But if you had to force me to say, hey, in a very short period
20:18
of time, let's get the narrative.
20:21
I think the way you think about this, at least the way I think
20:25
about this is really two pieces. AI technology, regenerative AI
20:31
in particular I think is getting availed and will continue to get
20:35
availed really in two pieces. One is sort of the back end of
20:39
any company. What do I mean by that?
20:42
That means things like customer service, order fulfillment,
20:46
procurement to pay order to cash, all these sub processes
20:50
that a company needs to avail and perform a ton of technology
20:58
that is based on regenerative AI that companies are availing.
21:03
OK. And it's in the early innings
21:05
there. Some technologies are working,
21:08
some are still to be tested, but there's just a massive
21:11
proliferation of options set there.
21:14
And that includes, by the way, leveraging AI for R&D, for
21:18
formulations, right? Remember, I talked about we've
21:20
got this whole skin care line, multiple brands there.
21:23
Well, what's the next aspect of the skin care, right?
21:26
Like how do you formulate and how can you make it right So you
21:29
can use technology to all the back end, let's say heavy AI.
21:33
The other part that I see they'll continue to grow is on
21:37
the front facing right. So this is using AI simulators
21:43
to look and check your treatment plant.
21:47
So before we even go into a Med spa or a dermatology office, you
21:53
kind of go in the app and there's a bunch of them out
21:55
there, but it's really good level that technology getting
21:58
extremely sophisticated. It is getting really, really
22:02
interesting. I think you'll continue seeing
22:04
that and then you sort of tying that up into how do you actually
22:08
bring customers to your product? How do you bring to the funnel?
22:12
How do you take them through a consumer journey?
22:14
How do you take them from a sales lead to ultimately into an
22:18
actual transaction at a derm or Metspot, all that heavy, heavy
22:24
usage of AI coming to go. So that's sort of the front end.
22:28
But I would say the proliferation and AI is just,
22:31
it's compounding so fast, so fast that it's actually hard to
22:35
keep up. But you'll continue to see
22:37
innovation and deployment of AI on both sides of the fence
22:42
there. I can't wait to see what happens
22:45
with AII, think it's phenomenal what's happening.
22:48
And then putting it into our industry, putting it into play
22:51
will be very exciting to see. I think it's going to change for
22:54
the provider, it's going to change for the patient, it's
22:57
going to change everything. So we'll see where that takes us
23:00
in the next few years. So speaking about the next few
23:03
years, a couple of things. Without getting into specifics,
23:07
how do you decide which innovations are worth pursuing
23:12
in aesthetics and which are not? Yeah.
23:15
Look, we, we have this great opportunity to revance that.
23:18
We've got excellent brands that are doing extremely well.
23:22
And we sit at this sort of point where we have two businesses
23:26
like I explained, aesthetics and skin care.
23:29
And our goal is to continue investing in both sides.
23:32
We think there's upside and opportunity on both on
23:36
aesthetics and skin care and certainly a key part of the
23:41
framework of decision making, which is what you're pointing
23:44
to. How do you decide is around
23:47
making sure that we're investing enough R&D and time on the
23:55
scientific and aspect of the product #1 and #2 we're making
24:00
sure that we are bringing products to the market that are
24:05
safe and efficacy. And you sort of double click
24:07
from there and you say, okay, well on the static side, you can
24:09
clearly see us bringing more things on their regenerative
24:12
side like that's a must have. We're doing a lot of research
24:15
there. We've got some very interesting
24:17
innovation coming in the next couple of years that I think
24:20
will be extremely well received. And I think it's going to fit in
24:24
with some of the discussion we had around transformation versus
24:28
harmonization. I think it's going to fit really
24:31
well and we play in that field today.
24:33
And so we have a great opportunity to go and continue
24:36
developing that. We will continue to support new
24:40
innovation coming on the filler side with Tioxane.
24:43
So there's more coming there over the next five years.
24:46
I think that's going to be very, very exciting to see.
24:49
I think you'll continue to see evolution on the skin pen.
24:52
We're on in our 4th generation of skin pen.
24:56
So there's a lot more we can do there that's coming.
24:59
And you'll continue to see on the skin care side, a nice
25:04
expansion of our line up. So put a plug on some of our
25:08
other brands. So for instance, Penoxil, which
25:10
is our acne brand, you know, we few years ago we just had
25:14
benzoyl peroxide. Now we have salicylic acid.
25:16
Now we have adapting gel, we have all the formats, and we're
25:20
changing the application formats as well.
25:23
So I think there's a lot more there that we can do that the
25:26
ultimate then consumer really likes wants.
25:28
They want to be able to transport their product.
25:30
They want to quick and clean efficacy, serve results.
25:34
So there's a lot more that we can do there.
25:35
So we'll continue investing their sunscreen or Blues or
25:38
sunscreens, the number one mineral sunscreen in the US
25:41
right now #1 which is great, which is super proud of that
25:44
brand. And then you can do a lot more
25:45
there. So you'll see more than describe
25:47
directing brand, which is our anti aging brand that does well
25:51
at Ulta and other retailers. We're bringing some extremely
25:55
nice innovation there that is going to play into the
25:58
longevity, the sort of the skin health and sort of enhancements
26:03
on fine lines and wrinkles that I think will really please
26:07
people. And again, we're doing a lot of
26:08
research, we're doing a lot of clinicals on this stuff.
26:11
So we want to make sure that what we're bringing to the
26:13
market is extremely well received.
26:15
And then we've got this huge opportunity to do additional
26:19
products on eczema. We have a great brand, Saarna
26:22
that we have. It's really awesome.
26:25
It's over the counter treatment for eczema, but I think we can
26:28
do a lot more there. And so we'll continue to see
26:31
more innovation coming from that side.
26:33
OK, Well, sounds like you have big plans for 2026.
26:39
Any thoughts on where you might land in regenerative in exosomes
26:44
or stem cells or anything in the regenerative arena?
26:47
Absolutely. So look, you take the words out
26:49
of my mouth. Of course, exosomes is huge.
26:51
This is all sort of coming in 2026.
26:53
So we've got some really nice technology coming and it's all
26:56
playing around regenerative exosomes, autologous exosomes,
27:02
those kinds of things. And I usually leave a lot of
27:05
this discussion for the scientists on our team because
27:07
they're really good at this. But yes, absolutely on the
27:10
regenerative side. And that's sort of the idea
27:12
where we're spying towards procedures that really have
27:16
awesome outcomes for the patients.
27:18
And so you can definitely see us bringing more on the front in
27:22
2026. OK.
27:24
Well, we can't wait to see it. Couple of final questions that I
27:28
have for you, Nadine, is that you've worked across multiple
27:32
sectors when I was doing some research on you.
27:35
What about aesthetics feels most unique to you?
27:38
Just to really dive in fully as the CEO of one of the largest
27:42
aesthetics companies. Here's what gets me really
27:44
excited and a big reason why I'm here is I am super excited about
27:51
being able to bring products to the market that really have a
27:57
massive impact on people's lives.
27:59
It's it's really going to change your lifestyle.
28:02
Like it's really going to have an impact on how you feel about
28:06
yourself, how you feel about your skin, how you feel overall
28:10
as you take our products, right. So that part is what keeps me
28:13
going. And then you sort of go from
28:16
there. It's OK.
28:16
Well, then if that's what we're about, let's make sure that
28:20
we're doing all the research, we're investing in the science
28:24
to really bring products that are safe and efficacy and really
28:27
have an extreme positive outcome in a person's life.
28:32
So that ability to impact someone's life in an extremely
28:37
positive way is really, to me, it's an honor and and it really
28:41
keeps me very energized and working hard vis a vis other
28:46
businesses that I've fled and spent a lot of time on.
28:49
This is one of those rare opportunities where you can
28:52
actually make a huge impact, and I'm grateful for having that
28:55
opportunity. And I'm sure you will.
28:57
And I think that aesthetic companies have to take more bold
29:02
risks than most companies. What would you say the boldest
29:06
risk that aesthetic companies will need to take over the next
29:09
few years? Yeah.
29:12
Look, that's a great question. I think it's one of those things
29:16
where you have to think about how much you can push on
29:21
envelope, right, because it's around transformation versus
29:25
harmonization and statics. Companies can certainly have the
29:31
resources and the capital allocation to go come up with a
29:34
lot of things. However, what you have to
29:37
balance is are you putting products out in the market at
29:42
the expense of some long term issues to a patient, right?
29:45
So that's where the balance is. You want to be thoughtful around
29:48
that. You want to bring change in
29:50
people's lives, but not at a detriment, right?
29:53
So again, it's a big broad question you're asking.
29:55
So I'm giving a big broad answer to that, but that's the sort of
29:59
internal plug off war that you have, right?
30:03
What is too much And we all have to struggle with that and have
30:05
to have an answer in our own respective companies.
30:09
And look where we sit today. I can speak for ourself.
30:11
For us, it's really important that we're continuing down the
30:15
regenerative path. I think that's a very solid
30:17
path. And by definition, it's sort of
30:21
gives you certain guardrails, right?
30:22
It's whatever you put out there, it's going to be nice gentle,
30:26
steady enhancements, which we think bodes well for what the
30:30
trends and what the consumers want.
30:31
So I think we're feeling really good about that.
30:33
OK. And so let's wrap up with one
30:37
final question. Imagine the headline that you
30:41
would love to see written about revamped one year from now.
30:44
What would it say? I would love to be able to see a
30:49
massive accolade from our customers and our physicians
30:53
that revamped 2 point O is really the company that delivers
31:01
on their promise and their commitment and bringing
31:06
excellent science based products at at a customer service level
31:11
that is best in class. So if we could get that
31:15
accolade, you can social media front page, whatever prank your
31:21
choice, that is a huge acknowledgement of what we're
31:25
aspiring to continue to do. So I would love to see that.
31:29
I love that. That's a great way to sum things
31:32
up. And great episode, you know,
31:34
Thank you so much for joining us, Nadine.
31:36
Is there anything else that you'd like to share with the
31:38
listeners and viewers before we sign off?
31:41
Yeah, look, thank you for your time.
31:42
You've got an excellent show. It's an honor to be here.
31:46
I thank you for your time. Thank you for inviting me.
31:48
I hope we can do this again and I look forward to definitely
31:53
keeping up and listening to your other shows.
31:55
Absolutely. And, you know, we'd love to have
31:57
you back next year and hear about how the plans are coming
32:00
along and how things are going. And I look forward to meeting
32:03
you in Nashville next year. So thank you so much for your
32:06
time and for joining us. I'm sure this is probably one of
32:08
the busier weeks of your life. So thank you for taking some
32:11
time with us. We appreciate it.
32:13
And that's it for today's episode of the Doctor Randy
32:17
Show. I'll be back next week with
32:19
conversations that challenge the industry and shape the future.
32:23
Thanks so much, Nadine. Thank you.
32:26
Doctor Randy Boyett holds a PhD and is a recognized leader in
32:29
the aesthetics and medical industry.
32:31
She is not a licensed medical doctor.
32:34
All commentary and product recommendations are based on
32:37
industry expertise and are provided for informational
32:40
purposes only.